TIGAR and cervical carcinoma: These data further imply that inhibiting TIGAR sensitizes HPV18+ cervical cancer cells to the DNA-alkylating drug, cyclophosphamide and thus could add yet another therapeutic to the arsenal against virus-induced cancers.